219 related articles for article (PubMed ID: 24163280)
1. Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over.
Gupta A; Li S
Drugs Aging; 2013 Dec; 30(12):999-1008. PubMed ID: 24163280
[TBL] [Abstract][Full Text] [Related]
2. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).
Sang CN; Sathyanarayana R; Sweeney M;
Clin J Pain; 2013 Apr; 29(4):281-8. PubMed ID: 22801243
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia.
Chen C; Han CH; Sweeney M; Cowles VE
J Pharm Sci; 2013 Apr; 102(4):1155-64. PubMed ID: 23381946
[TBL] [Abstract][Full Text] [Related]
4. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Rauck RL; Irving GA; Wallace MS; Vanhove GF; Sweeney M
J Pain Symptom Manage; 2013 Aug; 46(2):219-28. PubMed ID: 23149085
[TBL] [Abstract][Full Text] [Related]
5. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study.
Wallace MS; Irving G; Cowles VE
Clin Drug Investig; 2010; 30(11):765-76. PubMed ID: 20818838
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes.
Kantor D; Panchal S; Patel V; Bucior I; Rauck R
J Pain; 2015 Dec; 16(12):1300-1311. PubMed ID: 26409117
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN).
Markley HG; Dunteman ED; Kareht S; Sweeney M
Clin J Pain; 2015 Jan; 31(1):58-65. PubMed ID: 25076463
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial.
Irving G; Jensen M; Cramer M; Wu J; Chiang YK; Tark M; Wallace M
Clin J Pain; 2009; 25(3):185-92. PubMed ID: 19333167
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients.
Jensen MP; Irving G; Rauck R; Wallace M; Sweeney M; Vanhove GF
Clin J Pain; 2013 Sep; 29(9):770-4. PubMed ID: 23370075
[TBL] [Abstract][Full Text] [Related]
10. Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.
Shaparin N; Slattum PW; Bucior I; Nalamachu S
Clin J Pain; 2015 Nov; 31(11):983-91. PubMed ID: 25811794
[TBL] [Abstract][Full Text] [Related]
11. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Mehta N; Bucior I; Bujanover S; Shah R; Gulati A
Health Qual Life Outcomes; 2016 Apr; 14():54. PubMed ID: 27037091
[TBL] [Abstract][Full Text] [Related]
12. Gabapentin for chronic neuropathic pain in adults.
Wiffen PJ; Derry S; Bell RF; Rice AS; Tölle TR; Phillips T; Moore RA
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007938. PubMed ID: 28597471
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview.
Argoff CE; Chen C; Cowles VE
Expert Opin Drug Deliv; 2012 Sep; 9(9):1147-60. PubMed ID: 22809245
[TBL] [Abstract][Full Text] [Related]
14. Gabapentin for once-daily treatment of post-herpetic neuralgia: a review.
Beal B; Moeller-Bertram T; Schilling JM; Wallace MS
Clin Interv Aging; 2012; 7():249-55. PubMed ID: 22866002
[TBL] [Abstract][Full Text] [Related]
15. Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin.
Freeman R; Wallace MS; Sweeney M; Backonja MM
Pain Med; 2015 Oct; 16(10):2000-11. PubMed ID: 26115203
[TBL] [Abstract][Full Text] [Related]
16. Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials.
Wang J; Zhu Y
J Dermatolog Treat; 2017 Feb; 28(1):65-77. PubMed ID: 27798973
[TBL] [Abstract][Full Text] [Related]
17. The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery.
Chen C; Cowles VE; Sweeney M
Curr Clin Pharmacol; 2013 Feb; 8(1):67-72. PubMed ID: 22946876
[TBL] [Abstract][Full Text] [Related]
18. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial.
Sandercock D; Cramer M; Biton V; Cowles VE
Diabetes Res Clin Pract; 2012 Sep; 97(3):438-45. PubMed ID: 22497967
[TBL] [Abstract][Full Text] [Related]
19. Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
Parsons B; Tive L; Huang S
Am J Geriatr Pharmacother; 2004 Sep; 2(3):157-62. PubMed ID: 15561647
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials.
Fan H; Yu W; Zhang Q; Cao H; Li J; Wang J; Shao Y; Hu X
J Clin Pharm Ther; 2014 Aug; 39(4):334-42. PubMed ID: 24806220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
